Review



triptolide treatment  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Santa Cruz Biotechnology triptolide treatment
    Figure 4. Paused Pol II Half-Life (t1/2) Decreases in FACT-Depleted S2 Cells (A–D) Chromatin from cells that had been treated with control dsRNA targeting EGFP or dsRNA targeting SSRP1 were incubated with 500-mM <t>triptolide</t> for 5, 10, 15, or 30 min or with 2% DMSO as control and subjected to ChIP-nexus using anti-Rpb3 antibodies. For each promoter where a typical Pol II ChIP-nexus footprint was observed (distance between positive and negative strand peak < 50 bp, position of Pol II footprint < 150 bp downstream of the TSS), spike-in normalized Pol II signal in a 51-bp window centered on the midpoint between paused Pol II positive and negative summits was determined, and the half-life of paused Pol II was calculated based on an exponential decay model. (A) Pol II in the pausing window at 18w as a function of time after addition of triptolide, in cells treated with EGFP (red) or SSRP1 (blue) dsRNAs. (B) Boxplot showing decreased paused Pol II half-life following SSRP1 depletion. p value was calculated with a two-sample Wilcoxon test, n = 998. (C) Heatmaps of Pol II ChIP-nexus data at various times after triptolide addition in EGFP and SSRP1 dsRNA-treated cells. (D) Boxplot showing fold change in pause half-life across highly paused (n = 411), moderately paused (n = 358), and lowly paused (n = 229) genes. p values were calculated using Wilcoxon rank sum test of pairwise comparisons. (E) A model for FACT function in promoter-proximal pausing and transcription-coupled histone modifications. In control cells (top panel), the +1 nucleosome is stabilized by FACT (Ramachandran et al., 2017). The +1 nucleosome in turn helps to maintain Pol II in the vicinity of the promoter-proximal pause, and tran- scription-coupled histone modifications H3K4me3 and H3K36me3 are normally deposited. Upon depletion of FACT, the +1 nucleosome is destabilized, and Pol II spends less time at the promoter-proximal pause. Hence, methyltransferases associated with elongating Pol II are allowed less time to place marks, leading to a broadening of H3K4me3 and relative depletion of H3K36me3 from more 50 portions of genes.
    Triptolide Treatment, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 21 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptolide treatment/product/Santa Cruz Biotechnology
    Average 93 stars, based on 21 article reviews
    triptolide treatment - by Bioz Stars, 2026-03
    93/100 stars

    Images

    1) Product Images from "A Role for FACT in RNA Polymerase II Promoter-Proximal Pausing."

    Article Title: A Role for FACT in RNA Polymerase II Promoter-Proximal Pausing.

    Journal: Cell reports

    doi: 10.1016/j.celrep.2019.05.099

    Figure 4. Paused Pol II Half-Life (t1/2) Decreases in FACT-Depleted S2 Cells (A–D) Chromatin from cells that had been treated with control dsRNA targeting EGFP or dsRNA targeting SSRP1 were incubated with 500-mM triptolide for 5, 10, 15, or 30 min or with 2% DMSO as control and subjected to ChIP-nexus using anti-Rpb3 antibodies. For each promoter where a typical Pol II ChIP-nexus footprint was observed (distance between positive and negative strand peak < 50 bp, position of Pol II footprint < 150 bp downstream of the TSS), spike-in normalized Pol II signal in a 51-bp window centered on the midpoint between paused Pol II positive and negative summits was determined, and the half-life of paused Pol II was calculated based on an exponential decay model. (A) Pol II in the pausing window at 18w as a function of time after addition of triptolide, in cells treated with EGFP (red) or SSRP1 (blue) dsRNAs. (B) Boxplot showing decreased paused Pol II half-life following SSRP1 depletion. p value was calculated with a two-sample Wilcoxon test, n = 998. (C) Heatmaps of Pol II ChIP-nexus data at various times after triptolide addition in EGFP and SSRP1 dsRNA-treated cells. (D) Boxplot showing fold change in pause half-life across highly paused (n = 411), moderately paused (n = 358), and lowly paused (n = 229) genes. p values were calculated using Wilcoxon rank sum test of pairwise comparisons. (E) A model for FACT function in promoter-proximal pausing and transcription-coupled histone modifications. In control cells (top panel), the +1 nucleosome is stabilized by FACT (Ramachandran et al., 2017). The +1 nucleosome in turn helps to maintain Pol II in the vicinity of the promoter-proximal pause, and tran- scription-coupled histone modifications H3K4me3 and H3K36me3 are normally deposited. Upon depletion of FACT, the +1 nucleosome is destabilized, and Pol II spends less time at the promoter-proximal pause. Hence, methyltransferases associated with elongating Pol II are allowed less time to place marks, leading to a broadening of H3K4me3 and relative depletion of H3K36me3 from more 50 portions of genes.
    Figure Legend Snippet: Figure 4. Paused Pol II Half-Life (t1/2) Decreases in FACT-Depleted S2 Cells (A–D) Chromatin from cells that had been treated with control dsRNA targeting EGFP or dsRNA targeting SSRP1 were incubated with 500-mM triptolide for 5, 10, 15, or 30 min or with 2% DMSO as control and subjected to ChIP-nexus using anti-Rpb3 antibodies. For each promoter where a typical Pol II ChIP-nexus footprint was observed (distance between positive and negative strand peak < 50 bp, position of Pol II footprint < 150 bp downstream of the TSS), spike-in normalized Pol II signal in a 51-bp window centered on the midpoint between paused Pol II positive and negative summits was determined, and the half-life of paused Pol II was calculated based on an exponential decay model. (A) Pol II in the pausing window at 18w as a function of time after addition of triptolide, in cells treated with EGFP (red) or SSRP1 (blue) dsRNAs. (B) Boxplot showing decreased paused Pol II half-life following SSRP1 depletion. p value was calculated with a two-sample Wilcoxon test, n = 998. (C) Heatmaps of Pol II ChIP-nexus data at various times after triptolide addition in EGFP and SSRP1 dsRNA-treated cells. (D) Boxplot showing fold change in pause half-life across highly paused (n = 411), moderately paused (n = 358), and lowly paused (n = 229) genes. p values were calculated using Wilcoxon rank sum test of pairwise comparisons. (E) A model for FACT function in promoter-proximal pausing and transcription-coupled histone modifications. In control cells (top panel), the +1 nucleosome is stabilized by FACT (Ramachandran et al., 2017). The +1 nucleosome in turn helps to maintain Pol II in the vicinity of the promoter-proximal pause, and tran- scription-coupled histone modifications H3K4me3 and H3K36me3 are normally deposited. Upon depletion of FACT, the +1 nucleosome is destabilized, and Pol II spends less time at the promoter-proximal pause. Hence, methyltransferases associated with elongating Pol II are allowed less time to place marks, leading to a broadening of H3K4me3 and relative depletion of H3K36me3 from more 50 portions of genes.

    Techniques Used: Control, Incubation



    Similar Products

    94
    Thermo Fisher triptolide treatment
    Triptolide Treatment, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptolide treatment/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    triptolide treatment - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    93
    Tocris triptolide treatment
    ADAR3 influences mRNA stability. ( A ) Scatterplot comparing mRNA decay rates in N2A-C and N2A-A3 cells following treatment with <t>triptolide</t> for 8 h. For each transcript and each cell line, the ratio between the normalized abundances at 0 and at 8 h was calculated and expressed as a log2 fold change. The plot shows the average ratio of the log2 fold change ( n = 4) in each cell line. The x-axis shows the value for N2A-C and the y-axis shows the values for N2A-A3 cells. Only the top 10% of stabilized or destabilized transcripts were considered significant. Destabilized transcripts in N2A-A3 cells are shown in red and stabilized transcripts in blue. See Methods for details. ( B ) Gene ontology enrichment test (GO: Biological processes) of destabilized (right) and stabilized (left) transcripts. The x-axis indicates Fold Enrichment, color signifies –log 10 False Discovery Rate (FDR) and the size of the dot indicates the number of genes in the dataset that belong to the pathway. ( C ) Scatter plot comparing changes in mRNA stability (x-axis) with changes in mRNA abundance (y-axis). The plot includes all transcripts with available mRNA stability data in the triptolide experiment, except those showing increased abundance after triptolide treatment. Differentially expressed transcripts are shown in blue. Pearson's correlations are shown in the figure. n = 6304 transcripts. ( D ) Scatter plot as in C including only the mRNAs that showed extreme changes in mRNA stability in the triptolide experiment (stability residual > 0.5 and stability residual < –0.5). Differentially expressed transcripts (FDR < 0.05) are shown in blue. Pearson's correlation is shown in the figure.
    Triptolide Treatment, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptolide treatment/product/Tocris
    Average 93 stars, based on 1 article reviews
    triptolide treatment - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    95
    MedChemExpress triptolide treatment group
    Pathological changes in the hippocampus of mTBI rat. A.HE staining showed that the swelling and rupture of rat cells were decreased after <t>triptolide</t> treatment. B. number of neuron cells. Swelling and ruptured nerve cells can be seen in the image, as shown by the black arrow. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. scale bar 100 µm, n=3. C. NeuN immunostaning (red). D. NeuN positive cells.comparison between groups on day 7, and day 3 each group. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. Data presented as mean + SD. n=5. The *,and # , indicate statistically significant differences.
    Triptolide Treatment Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptolide treatment group/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    triptolide treatment group - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress triptolide treatment
    Pathological changes in the hippocampus of mTBI rat. A.HE staining showed that the swelling and rupture of rat cells were decreased after <t>triptolide</t> treatment. B. number of neuron cells. Swelling and ruptured nerve cells can be seen in the image, as shown by the black arrow. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. scale bar 100 µm, n=3. C. NeuN immunostaning (red). D. NeuN positive cells.comparison between groups on day 7, and day 3 each group. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. Data presented as mean + SD. n=5. The *,and # , indicate statistically significant differences.
    Triptolide Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptolide treatment/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    triptolide treatment - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    95
    Selleck Chemicals inhibitor treatments
    Pathological changes in the hippocampus of mTBI rat. A.HE staining showed that the swelling and rupture of rat cells were decreased after <t>triptolide</t> treatment. B. number of neuron cells. Swelling and ruptured nerve cells can be seen in the image, as shown by the black arrow. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. scale bar 100 µm, n=3. C. NeuN immunostaning (red). D. NeuN positive cells.comparison between groups on day 7, and day 3 each group. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. Data presented as mean + SD. n=5. The *,and # , indicate statistically significant differences.
    Inhibitor Treatments, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inhibitor treatments/product/Selleck Chemicals
    Average 95 stars, based on 1 article reviews
    inhibitor treatments - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology triptolide treatment
    Figure 4. Paused Pol II Half-Life (t1/2) Decreases in FACT-Depleted S2 Cells (A–D) Chromatin from cells that had been treated with control dsRNA targeting EGFP or dsRNA targeting SSRP1 were incubated with 500-mM <t>triptolide</t> for 5, 10, 15, or 30 min or with 2% DMSO as control and subjected to ChIP-nexus using anti-Rpb3 antibodies. For each promoter where a typical Pol II ChIP-nexus footprint was observed (distance between positive and negative strand peak < 50 bp, position of Pol II footprint < 150 bp downstream of the TSS), spike-in normalized Pol II signal in a 51-bp window centered on the midpoint between paused Pol II positive and negative summits was determined, and the half-life of paused Pol II was calculated based on an exponential decay model. (A) Pol II in the pausing window at 18w as a function of time after addition of triptolide, in cells treated with EGFP (red) or SSRP1 (blue) dsRNAs. (B) Boxplot showing decreased paused Pol II half-life following SSRP1 depletion. p value was calculated with a two-sample Wilcoxon test, n = 998. (C) Heatmaps of Pol II ChIP-nexus data at various times after triptolide addition in EGFP and SSRP1 dsRNA-treated cells. (D) Boxplot showing fold change in pause half-life across highly paused (n = 411), moderately paused (n = 358), and lowly paused (n = 229) genes. p values were calculated using Wilcoxon rank sum test of pairwise comparisons. (E) A model for FACT function in promoter-proximal pausing and transcription-coupled histone modifications. In control cells (top panel), the +1 nucleosome is stabilized by FACT (Ramachandran et al., 2017). The +1 nucleosome in turn helps to maintain Pol II in the vicinity of the promoter-proximal pause, and tran- scription-coupled histone modifications H3K4me3 and H3K36me3 are normally deposited. Upon depletion of FACT, the +1 nucleosome is destabilized, and Pol II spends less time at the promoter-proximal pause. Hence, methyltransferases associated with elongating Pol II are allowed less time to place marks, leading to a broadening of H3K4me3 and relative depletion of H3K36me3 from more 50 portions of genes.
    Triptolide Treatment, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triptolide treatment/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    triptolide treatment - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    Image Search Results


    ADAR3 influences mRNA stability. ( A ) Scatterplot comparing mRNA decay rates in N2A-C and N2A-A3 cells following treatment with triptolide for 8 h. For each transcript and each cell line, the ratio between the normalized abundances at 0 and at 8 h was calculated and expressed as a log2 fold change. The plot shows the average ratio of the log2 fold change ( n = 4) in each cell line. The x-axis shows the value for N2A-C and the y-axis shows the values for N2A-A3 cells. Only the top 10% of stabilized or destabilized transcripts were considered significant. Destabilized transcripts in N2A-A3 cells are shown in red and stabilized transcripts in blue. See Methods for details. ( B ) Gene ontology enrichment test (GO: Biological processes) of destabilized (right) and stabilized (left) transcripts. The x-axis indicates Fold Enrichment, color signifies –log 10 False Discovery Rate (FDR) and the size of the dot indicates the number of genes in the dataset that belong to the pathway. ( C ) Scatter plot comparing changes in mRNA stability (x-axis) with changes in mRNA abundance (y-axis). The plot includes all transcripts with available mRNA stability data in the triptolide experiment, except those showing increased abundance after triptolide treatment. Differentially expressed transcripts are shown in blue. Pearson's correlations are shown in the figure. n = 6304 transcripts. ( D ) Scatter plot as in C including only the mRNAs that showed extreme changes in mRNA stability in the triptolide experiment (stability residual > 0.5 and stability residual < –0.5). Differentially expressed transcripts (FDR < 0.05) are shown in blue. Pearson's correlation is shown in the figure.

    Journal: Nucleic Acids Research

    Article Title: ADAR3 modulates neuronal differentiation and regulates mRNA stability and translation

    doi: 10.1093/nar/gkae753

    Figure Lengend Snippet: ADAR3 influences mRNA stability. ( A ) Scatterplot comparing mRNA decay rates in N2A-C and N2A-A3 cells following treatment with triptolide for 8 h. For each transcript and each cell line, the ratio between the normalized abundances at 0 and at 8 h was calculated and expressed as a log2 fold change. The plot shows the average ratio of the log2 fold change ( n = 4) in each cell line. The x-axis shows the value for N2A-C and the y-axis shows the values for N2A-A3 cells. Only the top 10% of stabilized or destabilized transcripts were considered significant. Destabilized transcripts in N2A-A3 cells are shown in red and stabilized transcripts in blue. See Methods for details. ( B ) Gene ontology enrichment test (GO: Biological processes) of destabilized (right) and stabilized (left) transcripts. The x-axis indicates Fold Enrichment, color signifies –log 10 False Discovery Rate (FDR) and the size of the dot indicates the number of genes in the dataset that belong to the pathway. ( C ) Scatter plot comparing changes in mRNA stability (x-axis) with changes in mRNA abundance (y-axis). The plot includes all transcripts with available mRNA stability data in the triptolide experiment, except those showing increased abundance after triptolide treatment. Differentially expressed transcripts are shown in blue. Pearson's correlations are shown in the figure. n = 6304 transcripts. ( D ) Scatter plot as in C including only the mRNAs that showed extreme changes in mRNA stability in the triptolide experiment (stability residual > 0.5 and stability residual < –0.5). Differentially expressed transcripts (FDR < 0.05) are shown in blue. Pearson's correlation is shown in the figure.

    Article Snippet: For triptolide treatment, cells were seeded at 300 000 cells per well in a 12-well plate and treated with 1 μM triptolide (Tocris) 24 h after seeding.

    Techniques:

    Pathological changes in the hippocampus of mTBI rat. A.HE staining showed that the swelling and rupture of rat cells were decreased after triptolide treatment. B. number of neuron cells. Swelling and ruptured nerve cells can be seen in the image, as shown by the black arrow. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. scale bar 100 µm, n=3. C. NeuN immunostaning (red). D. NeuN positive cells.comparison between groups on day 7, and day 3 each group. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. Data presented as mean + SD. n=5. The *,and # , indicate statistically significant differences.

    Journal: IBRO Neuroscience Reports

    Article Title: Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury

    doi: 10.1016/j.ibneur.2024.05.007

    Figure Lengend Snippet: Pathological changes in the hippocampus of mTBI rat. A.HE staining showed that the swelling and rupture of rat cells were decreased after triptolide treatment. B. number of neuron cells. Swelling and ruptured nerve cells can be seen in the image, as shown by the black arrow. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. scale bar 100 µm, n=3. C. NeuN immunostaning (red). D. NeuN positive cells.comparison between groups on day 7, and day 3 each group. ## P < 0.01 mTBI compared with the sham group in both day 3 and day 7; *P < 0.05, mTBI+TP compared with the mTBI group day 3 and day 7. Data presented as mean + SD. n=5. The *,and # , indicate statistically significant differences.

    Article Snippet: The rats in the triptolide treatment group were intraperitoneally injected with 0.2 mg/kg triptolide ( ) for a week.TP (Med Chem Express, USA#39,836) was dissolved in DMSO at a concentration of 2 mg/mL and diluted with normal saline to a final concentration of 0.2 mg/ mL.

    Techniques: Staining, Comparison

    Inflammatory-related factors A. IL-1β, B. TNF-α and C. IL-10; changes after triptolide treatment. D&E individual raw data of each factors after 3 days and 7 days. Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD. The *, # , indicate statistically significant differences. IL-1β; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 # P < 0.05, TNF-ɑ; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01, IL-10; mTBI Vs. Sham day3 * P < 0.05 , day 7 * P < 0.05, mTBI+TP Vs . mTBI; day3 ** P < 0.01, day 7 ** P < 0.01, n=10.

    Journal: IBRO Neuroscience Reports

    Article Title: Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury

    doi: 10.1016/j.ibneur.2024.05.007

    Figure Lengend Snippet: Inflammatory-related factors A. IL-1β, B. TNF-α and C. IL-10; changes after triptolide treatment. D&E individual raw data of each factors after 3 days and 7 days. Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD. The *, # , indicate statistically significant differences. IL-1β; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 # P < 0.05, TNF-ɑ; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01, IL-10; mTBI Vs. Sham day3 * P < 0.05 , day 7 * P < 0.05, mTBI+TP Vs . mTBI; day3 ** P < 0.01, day 7 ** P < 0.01, n=10.

    Article Snippet: The rats in the triptolide treatment group were intraperitoneally injected with 0.2 mg/kg triptolide ( ) for a week.TP (Med Chem Express, USA#39,836) was dissolved in DMSO at a concentration of 2 mg/mL and diluted with normal saline to a final concentration of 0.2 mg/ mL.

    Techniques: Comparison

    Triptolide downregulated IL-1β and NF-κB expressions. The relative mRNA expression was calculated using the formula 2– ΔΔ Ct. Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD. The indicate statistically significant differences. IL-1β; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 # P < 0.05, NF-kB; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01, n=8.

    Journal: IBRO Neuroscience Reports

    Article Title: Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury

    doi: 10.1016/j.ibneur.2024.05.007

    Figure Lengend Snippet: Triptolide downregulated IL-1β and NF-κB expressions. The relative mRNA expression was calculated using the formula 2– ΔΔ Ct. Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD. The indicate statistically significant differences. IL-1β; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 # P < 0.05, NF-kB; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01, n=8.

    Article Snippet: The rats in the triptolide treatment group were intraperitoneally injected with 0.2 mg/kg triptolide ( ) for a week.TP (Med Chem Express, USA#39,836) was dissolved in DMSO at a concentration of 2 mg/mL and diluted with normal saline to a final concentration of 0.2 mg/ mL.

    Techniques: Expressing, Comparison

    LC3B expression changes after triptolide treatment at different time points. (A): Representative LC3B positive (green) and DAPI (blue) merged image is shown. In the mTBI group, the positive expression index of autophagy protein LC3B was higher than both sham and mTBI + TP groups. The autophagy protein experimental group can be seen in the image. Scale bar = 50 μm. Immunofluorescence showed decreased expression of autophagy and aquaporin in rats treated with triptolide. (B): Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD. The *, #, indicate statistically significant differences. mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01 day 7, n=8. C. LC3B Western blot, D. Quantitative analysis of LC3B; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01 day 7, n=3.

    Journal: IBRO Neuroscience Reports

    Article Title: Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury

    doi: 10.1016/j.ibneur.2024.05.007

    Figure Lengend Snippet: LC3B expression changes after triptolide treatment at different time points. (A): Representative LC3B positive (green) and DAPI (blue) merged image is shown. In the mTBI group, the positive expression index of autophagy protein LC3B was higher than both sham and mTBI + TP groups. The autophagy protein experimental group can be seen in the image. Scale bar = 50 μm. Immunofluorescence showed decreased expression of autophagy and aquaporin in rats treated with triptolide. (B): Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD. The *, #, indicate statistically significant differences. mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01 day 7, n=8. C. LC3B Western blot, D. Quantitative analysis of LC3B; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01 day 7, n=3.

    Article Snippet: The rats in the triptolide treatment group were intraperitoneally injected with 0.2 mg/kg triptolide ( ) for a week.TP (Med Chem Express, USA#39,836) was dissolved in DMSO at a concentration of 2 mg/mL and diluted with normal saline to a final concentration of 0.2 mg/ mL.

    Techniques: Expressing, Immunofluorescence, Comparison, Western Blot

    AQP4 expression changes after triptolide treatment at different time points. (A): Representative AQP4 positive (green) and DAPI (blue) merged image is shown. In the mTBI group, the positive expression index of AQP4 was higher than the sham and mTBI + TP groups. The Aquaporin of an experimental group can be seen in the image. Scale bar = 50 μm. Immunofluorescence showed decreased expression of autophagy and aquaporin in rats treated with triptolide. (B): Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD, n=8. The *, #, indicate statistically significant differences. mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 # P < 0.05, day 7 # P < 0.05 day 7, n=8. C. LC3B Western blot, D. Quantitative analysis of LC3B; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01 day 7, n=3.

    Journal: IBRO Neuroscience Reports

    Article Title: Neuroprotective effect of triptolide on neuronal inflammation in rats with mild brain injury

    doi: 10.1016/j.ibneur.2024.05.007

    Figure Lengend Snippet: AQP4 expression changes after triptolide treatment at different time points. (A): Representative AQP4 positive (green) and DAPI (blue) merged image is shown. In the mTBI group, the positive expression index of AQP4 was higher than the sham and mTBI + TP groups. The Aquaporin of an experimental group can be seen in the image. Scale bar = 50 μm. Immunofluorescence showed decreased expression of autophagy and aquaporin in rats treated with triptolide. (B): Comparison between groups on day 3, comparison between groups on day 7, and day 3 and day 7 for each group. Data presented as mean + SD, n=8. The *, #, indicate statistically significant differences. mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01 , mTBI+TP Vs. mTBI; day3 # P < 0.05, day 7 # P < 0.05 day 7, n=8. C. LC3B Western blot, D. Quantitative analysis of LC3B; mTBI Vs. Sham day3 ** P < 0.01, day 7 ** P < 0.01, mTBI+TP Vs. mTBI; day3 ## P < 0.01, day 7 ## P < 0.01 day 7, n=3.

    Article Snippet: The rats in the triptolide treatment group were intraperitoneally injected with 0.2 mg/kg triptolide ( ) for a week.TP (Med Chem Express, USA#39,836) was dissolved in DMSO at a concentration of 2 mg/mL and diluted with normal saline to a final concentration of 0.2 mg/ mL.

    Techniques: Expressing, Immunofluorescence, Comparison, Western Blot

    Figure 4. Paused Pol II Half-Life (t1/2) Decreases in FACT-Depleted S2 Cells (A–D) Chromatin from cells that had been treated with control dsRNA targeting EGFP or dsRNA targeting SSRP1 were incubated with 500-mM triptolide for 5, 10, 15, or 30 min or with 2% DMSO as control and subjected to ChIP-nexus using anti-Rpb3 antibodies. For each promoter where a typical Pol II ChIP-nexus footprint was observed (distance between positive and negative strand peak < 50 bp, position of Pol II footprint < 150 bp downstream of the TSS), spike-in normalized Pol II signal in a 51-bp window centered on the midpoint between paused Pol II positive and negative summits was determined, and the half-life of paused Pol II was calculated based on an exponential decay model. (A) Pol II in the pausing window at 18w as a function of time after addition of triptolide, in cells treated with EGFP (red) or SSRP1 (blue) dsRNAs. (B) Boxplot showing decreased paused Pol II half-life following SSRP1 depletion. p value was calculated with a two-sample Wilcoxon test, n = 998. (C) Heatmaps of Pol II ChIP-nexus data at various times after triptolide addition in EGFP and SSRP1 dsRNA-treated cells. (D) Boxplot showing fold change in pause half-life across highly paused (n = 411), moderately paused (n = 358), and lowly paused (n = 229) genes. p values were calculated using Wilcoxon rank sum test of pairwise comparisons. (E) A model for FACT function in promoter-proximal pausing and transcription-coupled histone modifications. In control cells (top panel), the +1 nucleosome is stabilized by FACT (Ramachandran et al., 2017). The +1 nucleosome in turn helps to maintain Pol II in the vicinity of the promoter-proximal pause, and tran- scription-coupled histone modifications H3K4me3 and H3K36me3 are normally deposited. Upon depletion of FACT, the +1 nucleosome is destabilized, and Pol II spends less time at the promoter-proximal pause. Hence, methyltransferases associated with elongating Pol II are allowed less time to place marks, leading to a broadening of H3K4me3 and relative depletion of H3K36me3 from more 50 portions of genes.

    Journal: Cell reports

    Article Title: A Role for FACT in RNA Polymerase II Promoter-Proximal Pausing.

    doi: 10.1016/j.celrep.2019.05.099

    Figure Lengend Snippet: Figure 4. Paused Pol II Half-Life (t1/2) Decreases in FACT-Depleted S2 Cells (A–D) Chromatin from cells that had been treated with control dsRNA targeting EGFP or dsRNA targeting SSRP1 were incubated with 500-mM triptolide for 5, 10, 15, or 30 min or with 2% DMSO as control and subjected to ChIP-nexus using anti-Rpb3 antibodies. For each promoter where a typical Pol II ChIP-nexus footprint was observed (distance between positive and negative strand peak < 50 bp, position of Pol II footprint < 150 bp downstream of the TSS), spike-in normalized Pol II signal in a 51-bp window centered on the midpoint between paused Pol II positive and negative summits was determined, and the half-life of paused Pol II was calculated based on an exponential decay model. (A) Pol II in the pausing window at 18w as a function of time after addition of triptolide, in cells treated with EGFP (red) or SSRP1 (blue) dsRNAs. (B) Boxplot showing decreased paused Pol II half-life following SSRP1 depletion. p value was calculated with a two-sample Wilcoxon test, n = 998. (C) Heatmaps of Pol II ChIP-nexus data at various times after triptolide addition in EGFP and SSRP1 dsRNA-treated cells. (D) Boxplot showing fold change in pause half-life across highly paused (n = 411), moderately paused (n = 358), and lowly paused (n = 229) genes. p values were calculated using Wilcoxon rank sum test of pairwise comparisons. (E) A model for FACT function in promoter-proximal pausing and transcription-coupled histone modifications. In control cells (top panel), the +1 nucleosome is stabilized by FACT (Ramachandran et al., 2017). The +1 nucleosome in turn helps to maintain Pol II in the vicinity of the promoter-proximal pause, and tran- scription-coupled histone modifications H3K4me3 and H3K36me3 are normally deposited. Upon depletion of FACT, the +1 nucleosome is destabilized, and Pol II spends less time at the promoter-proximal pause. Hence, methyltransferases associated with elongating Pol II are allowed less time to place marks, leading to a broadening of H3K4me3 and relative depletion of H3K36me3 from more 50 portions of genes.

    Article Snippet: To control for the loss of Pol II ChIP signal after triptolide treatment, a spike-in control was prepared by incubating human chromatin extracts from GM12878 cells with a 1:1 mixture of Dynabeads Protein A and Dynabeads Protein G coupled to antibodies against human Pol II (N20, Santa Cruz) followed by washing with nexus washing buffers A to D. A fixed amount of Dynabeads and human Pol II ChIP mixture was then spiked into each S2 ChIP-nexus experiment.

    Techniques: Control, Incubation